olutasidenib (Rezlidhia)
Jump to navigation
Jump to search
Indications
- treatment adults with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation as detected by an FDA-approved test
Dosage
Adverse effects
- common 20%
- nausea, fatigue/malaise, arthralgia, constipation, leukocytosis, dyspnea, fever, rash, mucositis, diarrhea elevated serum ALT & serum AST
* boxed warning for risk of differentiation syndrome
Laboratory
Mechanism of action
- binds to & inhibits mutated IDH1 to reduce 2-hydroxyglutarate levels & restore normal cellular differentiation of myeloid cells
More general terms
References
- ↑ Shinkle M Healio: HemOnc today. Dec 2, 2022 https://www.healio.com/news/hematology-oncology/20221202/fda-approves-olutasidenib-for-certain-adults-with-acute-myeloid-leukemia
FDA approves olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation (press release) Dec 1, 2022 https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olutasidenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-idh1-mutation